GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Price-to-Owner-Earnings

Sangui Biotech International (Sangui Biotech International) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Price-to-Owner-Earnings?

As of today (2024-04-28), Sangui Biotech International's share price is $0.0015. Sangui Biotech International does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sangui Biotech International's Price-to-Owner-Earnings or its related term are showing as below:


SGBI's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), Sangui Biotech International's share price is $0.0015. Sangui Biotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00. Therefore, Sangui Biotech International's PE Ratio for today is N/A.

As of today (2024-04-28), Sangui Biotech International's share price is $0.0015. Sangui Biotech International's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Sangui Biotech International's PE Ratio without NRI for today is N/A.


Sangui Biotech International Price-to-Owner-Earnings Historical Data

The historical data trend for Sangui Biotech International's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Price-to-Owner-Earnings Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sangui Biotech International's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Price-to-Owner-Earnings falls into.



Sangui Biotech International Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sangui Biotech International's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0015/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sangui Biotech International  (OTCPK:SGBI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sangui Biotech International Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines